Dr. Reddy's and Nestle India to form JV for health science nutraceutical portfolio
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Subscribe To Our Newsletter & Stay Updated